Edwards is focused on positioning TAVR for long-term growth ... that those who received Edwards’ newest generation SAPIEN 3 Ultra RESILIA valve have experienced outstanding one-year outcomes.

The TAVR market has experienced a slowdown, with Edwards reducing its 2024 and second half of the year worldwide TAVR outlook to 5-7% year-over-year, down from the previously anticipated 8-10% growth.

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies, has recently faced challenges in its core ...

California-based Edwards (NYSE:EW) its only sell-equivalent rating on Wall Street amid 14 buy-equivalent ratings. Citing an FDA dataset from the company's Partner 3 trial for its TAVR heart valve ...

However, there is a large population af7licted with aortic stenosis that do not exhibit symptoms which is monitored rather than treated with TAVR. Edwards presented data from its EARLY TAVR trial ...

disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Edwards’ TAVR platform. Specifically, Edwards’ claims and ...

Edwards categorizes its therapies and technologies into four categories: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), Surgical Structural ...